Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype


如何引用文章

全文:

详细

Treatment of patients with metastatic breast cancer (BC) with a triple-negative phenotype represents the most difficult challenge for clinicians. The optimal chemotherapy regimens for triple-negative BC (TNBC) have not been determined for a long time. However, in the later periods were found molecular agents of application (6 subtypes of TNBC) for the specific therapeutic agent and were performed many studies and subunit analysis, examined appropriate drugs for TNBC. Cell lines of these subtypes have different anticancer drug sensitivity. The results of further studies of targeted drugs using as monotherapy or in combination with chemotherapy in patients with TNBC, in spite of molecular genetic evidence for their application, have fallen short of expectations, although have shown increase in progression-free survival and overall survival. The development of eribulin (nontaxane microtubule dynamics inhibitor) in 2010 significantly increased the possibility of therapy in patients with locally advanced and metastatic BC who had already received chronic treatment. According to the joint analysis of the randomized phase III EMBRACE trial and Study 301, which included data about 1864 patients, it was demonstrated that eribulin statistically significant improve overall survival compared with other drugs using as monotherapy in the general population and among patients with TNBC [statistically significant differences in overall survival was associated with the subgroup of TNBC in patients who had been treated with eribulin, in comparison with the control arm: 12.9 and 8.2 months, respectively (relative risk 0.74; 95% confidence interval, 0.60 to 0.92, p=0.006)]. This article deals with the own experience of successful and long-term eribulin application in young woman with TN metastatic BC who have had already received chronic treatment.

作者简介

E Karabina

Tula Region Oncology Center

Email: kev-251@yandex.ru
зав. отд-нием противоопухолевой лекарственной терапии ГУЗ ТООД 300040, Russian Federation, Tula, ul. Plekhanova, d. 201a

L Zhukova

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: zhukova.lyudmila@rambler.ru
д-р мед. наук, науч. сотр. отд-ния химиотерапии и комбинированного лечения злокачественных опухолей ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

参考

  1. Sorlie T, Perou C.M, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
  2. Rakha E.A, El-Sayed M.E, Green A.R et al. Prognostic markers in triple - negative breast cancer. Cancer 2007; 109: 25-32.
  3. Haffty B.G, Yang Q, Reiss M et al. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early - Stage Breast Cancer. J Clin Oncol 2006; 24 (36): 5652-7.
  4. Baser O, Wei W, Xie L et al. Retrospective study of patients with metastatic triple - negative breast cancer: survival, health care utilization, and cost. Commun Oncol 2012; 9: 8-14.
  5. Reis-Filho J.S, Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-18.
  6. Lehmann B.D, Bauer J.A, Chen X et al. Identification of human triple - negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67.
  7. Жукова Л.Г., Окружнова М.А., Часовникова Е.О. Эрибулин в лечении метастатического рака молочной железы с тройным негативным фенотипом. Фарматека. 2014; 17: 1-8.
  8. Fan Y, Xu B.N, Yuan P et al. Docetaxel - cisplatin might be superior to docetaxel - capecitabine in the first - line treatment of metastatic triple - negative breast cancer. Ann Oncol 2013; 24 (5): 1219-25.
  9. Bhattacharyya G.S, Basu S, Agarwal V et al. Single institute phase II study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple - negative. Eur J Cancer 2009.
  10. Gluz O, Nitz U.A, Harbeck N et al. Triple - negative high - risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann Oncol 2008; 19: 861-70.
  11. Frasci G, Comella P, Rinaldo M et al. Preoperative weekly cisplatin - epirubicin - paclitaxel with G-CSF support in triple - negative large operable breast cancer. Ann. Oncol 2009; 20: 1185-92.
  12. Pivot X.B, Li R.K, Thomas E.S et al. Activity of ixabepilone in oestrogen receptor - negative and oestrogen receptor - progesterone receptor 2-negative metastatic breast cancer. Eur J Cancer 2009; 45 (17): 2940-6.
  13. Baselga J, Zambetti M, Llombart-Cussac A et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27 (4): 526-34.
  14. Муфазалов Ф.Ф., Шарипова Н.С. Тройной негативный рак молочной железы: современное состояние проблемы и не совсем обычный случай лечения. Злокачественные опухоли. 2014; 1: 19-31.
  15. Perou C.M. Molecular stratification of triple - negative breast cancer. Oncologist 2011; 16 (Suppl. 1): 61-70.
  16. Prat A, Parker J.S, Karginova O et al. Phenotypic and molecular characterization of the claudin - low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
  17. Rouzier R, Perou C.V, Symmans W.F et al. Breast Cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2008; 11: 5678-85.
  18. Сarey L.A. Directed therapy of subtypes of triple - negative breast cancer. Oncologist 2011; 16 (Suppl 1): 71-8.
  19. Cortes J, O‘Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician,s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open - label randomized study. Lancet 2011; 377: 914-23. doi: 10.1016/S0140-6736 (11)60070-6.
  20. Kaufman P.A, Cortes J, Awada A et al. Phase III open - label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan. J Clin Oncol 2015; 33 (6): 594-601. doi: 10.1200/JCO. 2013.52.4892.
  21. Chris Twelves, Ahmad Awada, Javier Cortes et al. Subgroup Analyses from a Phase 3, Open - Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer: Breast Cancer: Basic and Clinical Research 2016: 10; 77-84.
  22. Борисов О.В., Вьюшков Д.М., Войцицкий В.Е. и др. Роль эрибулина в увеличении общей выживаемости больных раком молочной железы: резолюция по итогам заседания экспертного совета экспертов - онкологов Сибирского федерального округа «Одна предшествующая линия химиотерапии: регистрация Халавена во второй линии МРМЖ. Клинические доказательства и преимущество в общей выживаемости» (29 марта 2015 г., Иркутск). Сиб. онкол. журн. 2015; 4: 93-9.
  23. Twelves C, Cortes J, Vahdat L et al. Efficacy of eribulin in patients with metastatic breast cancer: a pooled analysis by HER2 and ER status. ASCO. 2014; post. 95.
  24. Инструкция по медицинскому применению препарата Халавен (РУ ЛП-001782 от 24.07.2012 (с изменениями от 25.11.2014)).
  25. Yoshida T, Ozava Y, Kimura T et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial - mesenchymal transition (EMT) to mesenchymal - epithelial transition (MET) states. Br J Cancer 2014; 110: 1497-505. doi: 10.1038/bjc.2014.80.

版权所有 © Consilium Medicum, 2016

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##